PRESCO reported FY’16 PAT of ₦21.7 billion, a significant improvement from the ₦2.5 billion reported in FY’15. The notable surge in bottom line was largely driven by a ₦24.9 billion revaluation gain on biological assets (FY’15: ₦1.1 billion). Excluding the revaluation gains however, earnings would still have come in very strong, with PBT doubling y/y to c.₦6.3 billion despite recording FX loss of ₦1.4 billion. In line with industry trend, the y/y earnings performance was majorl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.